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Human polymorphonuclear leukocytes (PMN) were incubated in the absence or presence of the calcium 
ionophore A23187 (6 PM) for 10 min at 37°C. They were then lysed by nitrogen cavitation and fractionated 
using Percoll gradients. Three major fractions of increasing density corresponding to plasma membrane, 
intracellular membranes and secretory granules were detected using [3H]concanavalin A, NADH-dehydro- 
genase and /?-D-glucuronidase as respective markers. In both cases, the acetyltransferase activity responsible 
for biosynthesis of paf-acether (platelet-activating factor of l-O-alkyl-2-acetyl-sn-glycero-3-phosphochol- 
ine) was detected in the intermediary fraction, the enzyme activity being increased 3-4fold in stimulated 
cells. From the comparison with the distribution ofavarious markers, it is concluded that in human PMN 
the final step of paf-acether assembly occurs in an intracellular membrane, possibly the endoplasmic reticu- 
lum. 
Platelet-activating factor Polymorphonuclear leukocyte Acetyltransferase Subcellular fractionation 
1. INTRODUCTION 
The biosynthetic pathways of formation of paf- 
acether (platelet-activating factor of 1-0-alkyl-2- 
acetyl-sn-glycero-3-phosphocholine) were exten- 
sively studied in various cells or tissues (reviews 
[l-3]). It is now well accepted that paf-acether is 
synthesized by remodelling of membrane phos- 
pholipids, i.e. deacylation of 1-0-alkyl-2-acyl-sn- 
glycero-3-phosphocholine by a phospholipase A2 
activity yielding the inactive precursor, lyso-paf- 
acether (1-0-alkyl-sn-glycero-3-phosphocholine) 
[4-61 and its subsequent acetylation by an acetyl- 
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American Societies for Experimental Biology, Anaheim, 
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Co4 : 1 -alkyl-sn-glycero3-phosphocholine acetyl-. 
transferase (EC 2.3.1.67) [7,8]. This enzyme can be 
stimulated several times by specific secretagogues 
in human neutrophils [9,10], peritoneal [l l] and 
alveolar macrophages [6] and eosinophils from pa- 
tients with eosinophilia 1121. Kinetic data sug- 
gested that an increase in the number of active en- 
zyme molecules rather than a change in kinetic 
parameters was responsible for the enhanced 
acetyltransferase activity [ 111. Recently, some 
evidence of a phosphorylation/dephosphorylation 
mechanism in acetyltransferase activation was 
shown using rat spleen microsomes [ 131. 
The aim of this study was to localize precisely 
the subcellular structure(s) supporting the 
acetyltransferase, in stimulated and unstimulated 
human polymorphonuclear leukocytes (PMN). 
Among the various human and animal cells so far 
studied, the PMN are those which generate the 
highest amount of paf-acether [14]. 
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2. MATERIALS AND METHODS 
t3H]~oncanavalin A (60 Ci/mmol) and [N- 
~e~~y~-‘4C]piatelet-activating factor (50 mCi/ 
mmol) were purchased from Amersham, England; 
[3H]acetyl-CoA (4.8 Ci/mmol) and uridine 
diphosphate [‘4C]ga1actose (250-360 mCi/mmol) 
from New England Nuclear, Dreieich; Plasmagel@ 
from Laboratoires Roger Bellon, Neuilly, France; 
Percoll@ from Pharmacia, Uppsala. I-O-Hexade- 
cyl-sn-glycero-3-phosphocholine was obtained 
from Tebu S.A., Le Perray and Yvelines, France. 
Acetyl-CoA, fatty acid-free bovine serum 
albumin, calcium ionophore A23187 and all other 
chemicals were obtained from Sigma, St Louis, 
MO. 
2.1. Isolation and activation of PMN 
PMN isolation on a Percoll gradient is detailed 
in [IS]. Briefly, the leucocyte-rich supernatants of 
human blood treated with Plasmagel were frac- 
tionated on Percoll(l5.4 ml Percoll, buffered with 
6.6 ml of 490 mM NaCl, 33 mM Tris-HCl, pH 
7.4). Centrifugation was performed at 48000 x g 
for 10 min. Neutrophils concentrated in a lower 
band were collected and washed twice with buffer. 
After cell surface labelling with [3H]concanav~in 
A, PMN were washed twice in a solution contain- 
ing (mM): Hepes, 4.2, pH 7.4; NaCl, 137; KCI, 
75.6; glucose, 5.5. Finally, cells (106) were 
suspended in 1 ml washing buffer supplemented 
with 1.3 mM CaCl2 and 1 mM MgCl2 and in- 
cubated with 6 PM A23187 for 10 min at 37°C). 
The stimulation was stopped by adding 40 ml cold 
isotonic washing buffer. 
2.2. Subcellular fractionation of PMN 
As in [IS], cells were resuspended in an isotonic 
lysis buffer consisting of 100 mM KCI, 5 mM 
MgCI2, 1 mM ATP, 25 mM Tris-HCl (pH 9.6). 
PMN were lysed by nitrogen cavitation using a 
pressure of 40 bar and an equilibration time of 
20 min. After centrifugation at 1000 x g for 
15 min, the supernatant was mixed with Percoll 
(4 ml supernatant, 11 ml Percoll and 2.2 ml dis- 
tilled water, buffered with 4.8 ml of 400 mM KCl, 
20 mM MgC12, 400 mM Tris-HCl, pH 9.05). Cen- 
trifugation was performed at 160000 x g for 
15 min and 11 fractions of 2 ml were collected 
from the top of the tube. Each fraction was then 
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centrifuged at 200000 x g for 45 min in 8 ml buf- 
fer and each pellet was used for further 
determinations. 
2.3. Assay for acety~f~~nsfer~se 
Acetyltransferase activity was determined as in 
]I I] by measuring the transfer of [3H)acetate from 
[3H]acetyl-CoA (2OOpM, 0.5 $X100 nmol) to 
lyso-paf-acether (40 PM) used as an acceptor in the 
reaction mixture (0.5 ml, pH 7.0) containing 
(mM): Hepes, 4.2; NaCl, 137; KCI, 2.6; CaC12, 
0.65; MgC12, 0.5 and 0.25% bovine serum 
albumin. Incubations were performed for 10 min 
at 37°C under conditions where paf-acether pro- 
duction remained Iinear with time and protein con- 
centration. They were stopped by addition of 1 ml 
methanol containing I-[r4C]paf-acether (3000 
dpm) as an internal standard. After extraction, the 
amounts of paf-acether found in the assay are ex- 
pressed in nmol/min per mg protein. 
2.4. Other methods 
Enzyme markers were determined as reported 
[ 15,161, except for succinate-cytochrome c reduc- 
tase which was tested by the method of Tisdale 
1171. Protein was measured by the method of 
Lowry et al. 1181 in the presence of SDS (0.07~0, 
w/v). Radioactivity was evaluated with a Packard 
Tri-carb 4530 spectrometer equipped for 
automatic quenching correction. 
3. RESULTS 
As shown in fig.1 and in agreement with our 
previous results [ 151, fractionation of PMN lysates 
on Percoll gradients allowed a clear separation be- 
tween a low-density protein peak corresponding to 
[3H]~on~anava1in A, used as a plasma membrane 
marker and a high-density protein peak coinciding 
with P-D-glucuronidase, a secretory granule 
marker. Results were essentially the same in 
A23 187-stimulated and in resting PMN, except for 
a lower recovery of material from stimulated cells 
in both fractions. Indeed, A23187 treatment 
decreased the protein content of the lysate by 25 t 
7% (mean -t SD, n = 5) and that of the granule 
peak by 42 rt 3% (n = 5). This probably reflects 
some loss of adherent cells as well as granule 
discharge. 
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Fig.1. Subcellular fractionation of resting and A23187-stimulated PMN on Percoll gradients. This represents a typical 
profile obtained from the same pool of PMN and is repres&tative of 5 experiments with similar results. 
However, acetyltr~sferase activity did not coin- 
cide with any of the 2 markers previously men- 
tioned. In resting PMN, it was detected as a broad 
intermediary peak with the appearance of a 
shoulder, as depicted in fig. 1. Co~~rming previous 
results [ 10,141, A23 187 treatment resulted in a 
dramatic increase in acetyltransferase activity, 
which was then recovered as a unique peak focus- 
ing at an intermediary density (fig.1). These data 
were further confirmed by determination of rhe 
specific activity of the enzyme in the 3 fractions. It 
was always the highest in the intermediary fraction 
for both resting and activated PMN (table 1). To 
identify the membrane supposing acetyltransfer- 
ase activity more clearIy, stimulated PMN were 
fractionated on Percoll gradients and the distribu- 
tion of acetyitransferase was compared to that of 
various markers. Acetyltransfer~e profile was 
clearly different from those of galactosyltransfer- 
ase (a marker for Goigi membranes) and succinate- 
Table I 
Specific activity of acetyltransferase in subcelIular 
fractions obtained from resting and A23 187-stimulated 
PMN 
Resting stimulated 
PMN PMN 
Plasma membrane fraction 0.3 I 0.1 2.7 jl 2.0 
Intermediary fraction 2.8 -t 1.3 10.6 f. 2.3 
Granule fraction 1.4 f 1.0 0.4 r_f 0.4 
Results (mean Jo SD, 6 experiments) are given in 
nmol/min per mg protein 
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Fig.2. Subcellular distribution of acetyl transferase 
(- --) and of various markers (-) in 
A23187-stimulated PMN. Data are representative of 5 
experiments (except for galactosyltransferase, 2 
experiments), with similar results. 
cytochrome c reductase, a mitochondrial marker, 
besides those of [3H]concanavalin A and P-D- 
glucuronidase (fig.2). However, although not ab- 
solute, some coincidence appeared with the peak 
of NADH dehydrogenase, used as a marker for en- 
doplasmic reticulum [ 15,161. 
4. DISCUSSION 
Taken together, our data clearly indicate that 
PMN acetyltransferase is localized in a membrane 
fraction different from plasma membrane, granule 
membrane, mitochondria and Golgi membranes. 
To the best of our knowledge, this is the first time 
that the final step of paf-acether biosynthesis has 
been shown to occur in an intracellular membrane, 
possibly the endoplasmic reticulum. It is in- 
teresting to compare such a finding with a similar 
observation dealing with the localization of 
cyclooxygenase and thromboxane synthetase in the 
dense tubular system from human platelets 
[19,20]. Therefore, this is a further example of a 
lipid mediator released from cells, the synthesis of 
which does not occur in the plasma membrane or 
in a secretory organelle. This immediately raises 
the question as to the mechanism allowing paf- 
acether transfer from its site of synthesis to the 
plasma membrane and about the process of its 
transport through the membrane. Such a role 
could be partially devoted to a transfer protein 
specific for paf-acether [21]. Indeed, preliminary 
studies revealed that paf-acether synthesized in 
response to A23187 treatment and not yet released 
from PMN was mostly found in plasma membrane 
and granules, indicating that some redistribution 
from the site of synthesis did occur. 
Our data may also help in understanding the 
mechanism of acetyltransferase activation. It is 
now generally accepted that specific stimulation of 
various cells triggers 2 synergistic pathways involv- 
ing diacylglycerol and protein kinase C, on the one 
hand, and inositol triphosphate, Ca2+ and 
Ca2+-(calmodulin)-dependent protein kinases on 
the other [22]. Since some preliminary evidence ex- 
ists that activation of acetyltransferase might in- 
volve a phosphorylation step [13], one can 
speculate that the putative protein kinase responsi- 
ble for this would have to reach the intracellular 
membrane containing the acetyltransferase. Such a 
point is certainly important to consider in the light 
of the properties of the various protein kinases so 
far described. 
In conclusion, as outlined above, this study 
opens a series of important questions relevant to 
the biology of paf-acether. However, although 
acetyltransferase represents the final step of paf- 
acether assembly, other studies are still needed to 
determine the subcellular localization of phospho- 
lipid precursors as well as of phospholipase AZ. 
Moreover, whether such a localization of acetyl- 
transferase in an intracellular membrane is a 
general feature will require further investigations 
dealing with other cell types capable of synthesiz- 
ing paf-acether. In this respect, preliminary data 
seem to indicate that this could be the case for 2 
tumor cell lines, Krebs ascites cell (P. Fontan et al., 
in preparation) and HL60 (M. Record et al., in 
preparation). 
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